Sunday, September 20, 2026

Moderna Stock Is 5.22% Up So Far Today

ViaNews Editorial Team

November 20, 2020

Moderna Stock Is 5.22% Up So Far Today

According to today's article on Bloomberg Quint, "EU Could Approve BioNTech, Moderna Vaccines in December."

Shares of Moderna rose 5.22% to $97.61 at 17:05 EST on Friday, after one sequential sessions in a rows of gains. The Nasdaq Stock Market is sliding 0.42% to $11855, after one consecutive sessions in a rows of gains, on what seems, so far, a somewhat negative trend exchanging session on The Nasdaq Stock Market.

According to yesterday's article on Bloomberg Quint, "Moderna Vaccine Production Is Gearing Up, Partner Lonza Says."

Moderna's last close was $92.77, below its 52-week high of $103.2.

Moderna's sales growth is 1216.8% for the current quarter and 2299% for the next. The company's growth estimates for the ongoing quarter is a negative 67.6% and positive 142.9% for the next.

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's stock is valued at $97.61 at 17:05 EST, below its 52-week high of $103.2 and way above its 52-week low of $17.68.

Moderna's value is way higher than its 50-day moving average of $75.37 and way above its 200-day moving average of $68.93.

Moderna vaccine found highly effective at preventing covid. According to Bloomberg Quint on Mon Nov 16, "Moderna shares rised more than 9% in pre-market U.S."

According to MarketWatch on Mon Nov 16, "Stock futures surge as Moderna says coronavirus vaccine is 94.5% effective in trial."

Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

Update: Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

According to MarketWatch on Mon Nov 16, "Moderna shares have surged 18% in premarket on coronavirus vaccine trial data."

Stocks making the biggest moves in the premarket: Moderna, casper sleep, Uber, tapestry & more. According to CNBC on Mon Nov 16, "The stocks making the biggest moves in premarket trading include Moderna, Casper Sleep, Uber, Tapestry, and more.."

According to Bloomberg Quint on Mon Nov 16, "NYC-Linked Stocks Climb on Optimism Over Moderna Vaccine Results."

Stocks making the biggest moves midday: Moderna, simon property, bbva, virgin galactic & more. According to CNBC on Mon Nov 16, "Moderna gets a boost from positive vaccine trial data."

According to Bloomberg Quint on Mon Nov 16, "European Stocks Surge to February High on Moderna Vaccine Study."

According to Bloomberg Quint on Mon Nov 16, "Moderna Adds to Vaccine Hope; New California Curbs: Virus Update."

According to Bloomberg Quint on Tue Nov 17, "Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com